Highlights Celyad Oncology SA

Equities

CYAD

BE0974260896

Market Closed - Euronext Bruxelles Other stock markets 11:35:14 2024-04-30 am EDT			5-day change	1st Jan Change
0.325 ^EUR	-1.52%		-1.52%	-16.67%

Apr. 04	Celyad Oncology SA Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Feb. 09	Celyad Oncology Seeks Termination of Reporting Obligations to US SEC	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Celyad Oncology SA Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 04	CI
Celyad Oncology Seeks Termination of Reporting Obligations to US SEC	Feb. 09	MT
Celyad Oncology SA Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-04	CI
Celyad Oncology's American Depositary Shares to Be Delisted from Nasdaq	23-05-16	MT
Celyad Oncology Receives Delisting Notice From Nasdaq	23-05-15	MT
Forecast-Beating Apple Results Lift Exchange-Traded Funds, Equity Futures Pre-Bell Friday	23-05-05	MT
Belgium's Celyad Oncology to Delist ASDs from Nasdaq	23-05-05	MT
Celyad Oncology in Breach of Nasdaq's Listing Rule	23-04-04	MT
Celyad Oncology Announces Publication of Data from Its Phase 1 Think Study of CYAD-01	23-02-09	CI
Celyad Oncology Provides Update on Clinical Trial Programs	22-10-12	CI
Cellistic completed the acquisition of Manufacturing Business Unit of Celyad Oncology from Celyad Oncology SA.	22-09-29	CI
Celyad Oncology to Divest Cell Therapy Facility in Belgium for $6 Million	22-09-20	MT
Cellistic emtered into asset purchase agreement to acquire Manufacturing Business Unit of Celyad Oncology from Celyad Oncology SA for ?6 million.	22-09-19	CI
Celyad Oncology SA Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-05	CI
Celyad Oncology Says FDA Lifts Clinical Hold on Phase 1b Trial of Colorectal Cancer Combination Therapy	22-08-01	MT
Celyad Oncology Sa Announces Fda Lifts Clinical Hold of Cyad-101-002 Phase 1B Trial	22-08-01	CI
Celyad Oncology SA Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-06	CI
Celyad Oncology SA Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-24	CI
Celyad Says FDA Places Early-Stage Colorectal Cancer Trial on Clinical Hold	22-03-02	MT
Celyad Oncology Announces Clinical Hold of CYAD-101-002 Phase 1b Trial	22-03-02	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Celyad Oncology SA

Equities

CYAD

BE0974260896

Highlights

Filters